Suh H, Jung E J, Kim T H, Lee H Y, Park Y H, Kim K W
Department of Chemistry, Pusan National University, South Korea.
Cancer Lett. 1997 Feb 26;113(1-2):117-22. doi: 10.1016/s0304-3835(97)04604-1.
Ursodeoxycholic acid (UDCA) and its derivatives were examined for anti-angiogenic activities by using the chick embryo chorioallantoic membrane (CAM) assay. The presence of UDCA or its derivatives inhibited angiogenesis in a dose-dependent manner; the dose required for half-maximal inhibition (ID50) was 4 microg per CAM for UDCA. The conjugate forms of UDCA with glycine methyl ester (HS-1030), L-leucine benzyl ester (HS-1068) and L-leucine methyl ester (HS-1133) were showing ID50 of 0.09, 0.08 and 0.6 microg per CAM, respectively. Also, the effect of UDCA and its derivatives on the viability of calf pulmonary artery endothelial (CPAE) cells was examined. Among them, HS-1030 effectively reduced the viability of CPAE cells in a concentration-dependent manner. Based on these results, we speculated that HS-1030 might be a promising candidate as angiogenesis inhibitor for use in the management of diseases accompanied by uncontrolled angiogenesis including solid tumor.
通过鸡胚绒毛尿囊膜(CAM)试验检测了熊去氧胆酸(UDCA)及其衍生物的抗血管生成活性。UDCA或其衍生物的存在以剂量依赖的方式抑制血管生成;UDCA对每片CAM半最大抑制所需剂量(ID50)为4微克。UDCA与甘氨酸甲酯(HS - 1030)、L - 亮氨酸苄酯(HS - 1068)和L - 亮氨酸甲酯(HS - 1133)的共轭形式每片CAM的ID50分别为0.09、0.08和0.6微克。此外,还检测了UDCA及其衍生物对小牛肺动脉内皮(CPAE)细胞活力的影响。其中,HS - 1030以浓度依赖的方式有效降低了CPAE细胞的活力。基于这些结果,我们推测HS - 1030可能是一种有前景的血管生成抑制剂候选物,可用于治疗伴有不受控制的血管生成的疾病,包括实体瘤。